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Objectives: AmpC β-lactamases are classified as Amber Class C and Bush Group
1. AmpC β-lactamases can hydrolyze broad and extended-spectrum cephalosporins,
and are not inhibited by β-lactamase inhibitors such as clavulanic acid. This study
was conducted to identify DHA-23, a novel plasmid-mediated and inducible AmpC
β-lactamase obtained from Enterobacteriaceae.
Methods: A total of 210 carbapenem-resistant Enterobacteriaceae isolates were
collected from a medical center (comprising two branches) in Northern Taiwan during
2009–2012. AmpC β-lactamase genes were analyzed through a polymerase chain
reaction using plasmid DNA templates and gene sequencing. The genetic relationships
of the isolates were typed using pulsed-field gel electrophoresis following the digestion
of intact genomic DNA by using XbaI.
Results: Three enterobacterial isolates (one Escherichia coli and two Klebsiella
pneumoniae) were obtained from three hospitalized patients. All three isolates
were resistant or intermediately susceptible to all β-lactams, and exhibited reduced
susceptibility to carbapenems. These three isolates expressed a novel AmpC
β-lactamase, designated DHA-23, approved by the curators of the Lahey website.
DHA-23 differs from DHA-1 and DHA-6 by one amino acid substitution (Ser245Ala),
exhibiting three amino acid changes compared with DHA-7 and DHA-Morganella
morganii; three amino acid changes compared with DHA-3; four amino acid changes
compared with DHA-5; and eight amino acid changes compared with DHA-2
(>97% identity). This AmpC β-lactamase is inducible using a system involving
ampR.
Conclusion: This is the first report to address DHA-23, a novel AmpC β-lactamase.
DHA-type β-lactamases are continuous threat in Taiwan.
Keywords: AmpC beta-lactamase, Enterobacteriaceae, antimicrobial resistance epidemiology
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Introduction
AmpC enzymes are located in the bacterial periplasm, with the
exception of the AmpC β-lactamase of Psychrobacter immo-
bilis, which is secreted mainly into the external medium (Feller
et al., 1997). They are active on cephalosporins, cephamycins
(such as cefoxitin), oxyiminocephalosporins (such as ceftazidime
and cefotaxime), and monobactams (such as aztreonam). AmpC
β-lactamases are classiﬁed according to their Amber molecu-
lar structure as belonging to Class C, whereas according to
function, they are classiﬁed into Group 1 (Bush and Jacoby,
2010). The sequence of the ampC gene diﬀered from the
sequence of penicillinase-type β-lactamases such as TEM-1 but
similarly, had serine at its active site (Knott-Hunziker et al.,
1982). AmpC β-lactamases, in contrast to extended-spectrum
β-lactamases (ESBLs), can hydrolyze broad and extended-
spectrum cephalosporins, and are not inhibited by β-lactamase
inhibitors such as clavulanic acid. AmpC β-lactamases are
assumed to be chromosomally mediated; however, Klebsiella
pneumoniae, K. oxytoca, Proteus mirabilis, and Salmonella sp.
lack a chromosomal blaAmpC gene (Bergstrom et al., 1983;
Bauernfeind et al., 1989). Described plasmid-mediated AmpC
genes in a K. pneumoniae isolate from South Korea. There are
various types of plasmid-mediated AmpC β-lactamases: CMY,
MIR, MOX, LAT, FOX, DHA, ACT, ACC, and CFE (Jacoby,
2009). AmpR is a member of the LysR transcriptional regula-
tor family. During normal growth, in the absence of β-lactam
as an inducer, the AmpR regulator binds with a peptidoglycan
precursor uridine pyrophosphoryl-N-acetyl muramyl-L-alanyl-
D-glutamylmeso-diaminopimelic acid-D-alanyl-D-alanine (UDP-
N-acetylmuramic acid peptide). AmpR- UDP-N-acetylmuramic
acid peptide complex binds to the operator site between the
ampC and ampR structural genes, leading to the repression of
ampC expression. Displacement of the UDP-N-acetylmuramic
acid peptides signals a conformational change in AmpR, which
activates the transcription of ampC. AmpR mutations are less
common but can also result in high-constitutive or hyperin-
ducible phenotypes (Kaneko et al., 2005). Resistance caused by
plasmid-mediated AmpC β-lactamase is less common than the
production of ESBLs, but may be more diﬃcult to detect. The
purpose of this study was to identify DHA-23, a novel plasmid-
mediated and inducible AmpC β-lactamase identiﬁed in clinical
enterobacterial isolates that were obtained from a hospital in
Northern Taiwan.
Materials and Methods
Isolates and Data Collection
A total of 210 carbapenem-resistant Enterobacteriaceae isolates
were collected from a medical center (comprising two branches)
in Northern Taiwan from 2009 to 2012, including 100 K. pneu-
moniae, 53 Escherichia coli, 41 Enterobacter cloacae, and 16 other
isolates (one K. oxytoca, one Citrobacter freundii, two Providencia
rettgeri, eight Serratia sp., and four E. aerogenes). The isolates
were identiﬁed using the VITEK2 system (bioMérieux Vitek
Systems Inc., Hazelwood, MO, USA).
Polymrase Chain Reaction Detection of
Carbapenemase Genes and Insertion
Sequences
The carbapenemase-encoding genes were detected using poly-
merase chain reaction (PCR) methods as previously suggested by
Woodford et al. (2006) and Ellington et al. (2007). All primers
used in this study, such as blaTEM-type, blaSHV-type, blaCTX−M-
type, blaCMY-type, and blaDHA-type primers, were as described
previously (Tenover et al., 1995; Chung et al., 2011; Qi et al., 2011;
Huang et al., 2012). Sequence similarity searches were conducted
using the BLAST program1.
Pulsed-Field Gel Electrophoresis
The isolates were compared using pulsed-ﬁeld gel electrophore-
sis (PFGE; Seifert et al., 2005) following the digestion of intact
genomic DNA by using XbaI (Biolabs, UK). The XbaI restriction
proﬁles were initially compared using visual inspection accord-
ing to the criteria of Tenover et al. (1995). A computer-assisted
analysis was performed using BioNumerics (Applied Maths, Sint-
Martens-Latem, Belgium) software.
Conjugation and Electrotransformation
Experiments
Plasmid DNAs were extracted using the Qiagen Plasmid
Puriﬁcation Midi Kits (Qiagen, Courtaboeuf, France). Plasmid
1http://www.ncbi.nlm.nih.gov/blast
TABLE 1 | Minimum inhibitory concentrations (MICs) of three DHA-23
carrying enterobacterial isolates to antimicrobial agents.
Antimicrobial agent MIC (mg/L)
KP11∗ KP19∗ EC56∗
Ampicillin ≥32 ≥32 ≥32
Cefazolin ≥64 ≥64 ≥64
Cefoxitin ≥64 ≥64 ≥64
Cefuroxime ≥64 ≥64 ≥64
Cefotaxime 128 128 128
Ceftazidime 64 32 128
Flomoxef ≥64 ≥64 ≥64
Cefpirome 16 16 ≥64
Ciprofloxacin ≥4 ≥4 ≥4
Moxifloxacin ≥8 ≥8 ≥8
Piperacillin-tazobactam ≥128 ≥128 ≥128
Trimethoprim-sulfamethoxazole ≥320 ≥320 ≥320
Amikacin ≥64 ≥64 ≥64
Gentamicin ≥16 ≥16 ≥16
Tigecycline 4 2 ≤0.5
Colistin ≤0.5 ≥16 ≤0.5
Ertapenem 2 2 4
Meropenem 0.12 0.12 0.12
Imipenem 2 2 1
Doripenem 0.5 0.25 0.06
∗KP11 and KP19 expressed TEM-1, SHV-11, CTX-M-14, and DHA-23, EC56
expressed TEM-1, CTX-M-14, CMY-2, and DHA-23.
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FIGURE 1 | Alignment of the deduced amino-acid sequences of DHA-23 with those of other DHA type AmpC enzymes. Identical amino-acids are marked
with dashes. The underlined amino-acids are those that may be involved in the catalytic site of these AmpC enzymes, including the β-lactamase active site S–V–S–K
and the conserved triad K–T–G. DHA-MM, DHA-Morganella morganii.
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FIGURE 2 | Alignment of the deduced amino-acid sequences of the AmpR protein of DHA-23 with those of other DHA type AmpC enzymes.
FIGURE 3 | Genetic environment of blaDHA-23.
conjugation experiments were performed using E. coli DH5α
as the recipient (Poirel et al., 1999b). Transconjugants were
selected on Luria–Bertani agar plates supplemented with
sodium azide (100 mg/L) and cefotaxime (2 mg/L). In addi-
tion, cefoxitin (8 mg/L) was added to prevent the selection
of ESBL-producing transconjugants. Electrotransformants were
selected on agar containing cefotaxime (2 mg/L) or cefoxitin
(8 mg/L).
Minimum Inhibitory Concentrations
Minimum inhibitory concentrations (MICs) were determined
using the agar dilution method, which was repeated twice
for each sample. MICs of tested antibiotics were interpreted
according to Clinical and Laboratory Standards Institute
guidelines (M7–A9, CLSI, 2012). Antibiotics were purchased
from Sigma–Aldrich (St. Louis, MO, USA). Quality con-
trol was assured by testing Staphylococcus aureus ATCC
29213, E. coli ATCC25922, and Pseudomonas aeruginosa ATCC
27853.
Results
Novel AmpC β-Lactamase Discovered in Three
Enterobacterial Isolates
One E. coli (EC56) and two K. pneumoniae (KP11 and KP19)
isolates that exhibited resistance to cefoxitin, cefotaxime, and
ceftazidime were isolated from 3 adult patients hospitalized in
Northern Taiwan (Table 1). We had the designated DHA-23
approved by the curators of the Lahey website2. Using speciﬁc
primers for blaDHA−1, we obtained PCR fragments from plasmid
DNA preparations of E. coli EC56 and K. pneumoniae KP11 and
KP19. The deduced amino-acid sequence (Figure 1) indicated
that DHA-23 exhibited only one amino-acid change compared
with DHA-1 and DHA-6 (Ser245Ala), two amino acid changes
compared with DHA-7 and DHA-Morganella morganii (DHA-
MM; Barnaud et al., 1998), three amino acid changes compared
with DHA-3 (Wu et al., 2005), four amino acid changes com-
pared with DHA-5, and eight amino acid changes compared with
DHA-2 (>97% identity; Fortineau et al., 2001).
ampR Gene Found Immediately Upstream
from the ampC Gene
The 110-bp intercistronic region of ampC and ampR contained
the promoter sequences for ampC and ampR expression. This
region of blaDHA−23 was identical to the corresponding region of
2http://www.lahey.org/Studies/
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blaDHA−1 (Barnaud et al., 1998) and was 97.3% identical to that in
the chromosome ofM. morganii (Poirel et al., 1999a). The ampR
gene had an overlapping and divergently oriented promoter, as
described for other ampC–ampR regulatory systems (Bennett and
Chopra, 1993). Comparing the deduced amino-acid sequences
of the AmpR of DHA-23 with those of DHA-1 and M. mor-
ganii indicated >99% identity, with only one amino-acid change
in each case (Figure 2). A comparison of the AmpR of DHA-2
or the AmpR of DHA-3 revealed that they were at least >98%
similar, exhibiting two and three amino acid changes, respec-
tively. Similar to DHA-1, DHA-2, and DHA-3 (Barnaud et al.,
1998; Fortineau et al., 2001; Wu et al., 2005), the sequences sur-
rounding blaDHA showed that hybF was found upstream from the
ampC gene in DHA-1, DHA-2, and DHA-3, whereas orf-1 was
found downstream from the ampC gene only in DHA-1 (Barnaud
et al., 1998). Subsequently, hybF and orf-1 were investigated in
the sequences surrounding blaDHA−23. The hybF was identiﬁed
downstream of ampR, but orf-1 was not detected (Figure 3).
The hybF was coded for HybF and shared sequence homolo-
gies with hydrogenase subunits of E. coli (Menon et al., 1994).
Although ampR and blaDHA were mobilized from the chromo-
some ofM. morganii into a complex of In6–In7–sulI-type class-1
integrons in a strain of Salmonella enterica serovar Enteritidis
(Verdet et al., 2000), an integron carrying blaDHA−23 was not
detected in E. coli EC56 through PCR experiments employing
5′-CS and 3′-CS speciﬁc primers of class one integrons.
Clavulanic Acid Acts as An Inducer of DHA-23
E. coli EC56 contained 4 β-lactamases that corresponded to
TEM-1, CTX-M-14, CMY-2, and DHA-23. K. pneumoniae KP11
and KP19 both contained β-lactamases that corresponded to
TEM-1, SHV-11, CTX-M-14, and DHA-23. The genotyping of
isolates was conducted using PFGE by using XbaI digestion.
The results indicated that these two K. pneumoniae isolates had
similar pulsotypes. Conjugation experiments were subsequently
conducted, regardless of whether cefoxitin was used as a select-
ing agent, and the transfer of a plasmid coding the DHA-23
cephalosporinase into E. coli DH5α was not observed. The data
suggested that the blaDHA−23 plasmid is not self-transferable.
Electroporation experiments were then performed using plas-
mid DNA preparation of E. coli EC56 and K. pneumoniae KP11
and KP19. Ampliﬁcation and gene sequencing were used to ana-
lyze the plasmid DNA, and the results revealed that the E. coli
DH5α (pEC56) transformants contained two β-lactamases, TEM-
1 and DHA-23. The E. coli DH5α (pKP11) and E. coli DH5α
(pKP19) transformants contained only one β-lactamase, TEM-
1. However, repeated electrotransformation experiments failed to
obtain transformants carrying DHA-23 from KP11 and KP19.
The MIC of ceftazidime (128 mg/L) for E. coli EC56 was not
reduced by clavulanic acid. However, the MICs of cefotaxime
(0.12 mg/L) and ceftazidime (1.0 mg/L) for E. coliDH5α (pEC56)
increased in the presence of clavulanic acid, suggesting that
clavulanic acid may act as an inducer of DHA-23 (Table 2).
Discussion
This study presented a novel plasmid-mediated and inducible
AmpC β-lactamase obtained from Enterobacteriaceae, desig-
nated DHA-23 and approved by the curators of the Lahey
website. There are currently 22 DHA variants listed on the
site, most of which are assigned with no reference to the
sequence.
In Table 1, MICs of the DHA-23 carrying enterobacterial
isolates E. coli EC56 and K. pneumoniae KP11 and KP19 to
antimicrobial agents show that cephamycins (such as cefoxitin)
are not hydrolyzed by ESBLs, but are hydrolyzed by associated
AmpC β-lactamase. Class-C enzymes hydrolyze cephamycins
but do not hydrolyze extended-spectrum cephalosporins eﬀec-
tively. DHA-23 showed that the MICs did not substan-
tially increase for cefotaxime and ceftazidime when DHA-
23 was present in the transformants, whereas the MICs of
cefoxitin increased to 32 mg/L (Table 2). Resistance to the
carbapenems was variable. All strains were fully suscepti-
ble to meropenem and doripenem (Table 2). In general,
TABLE 2 | Minimum inhibitory concentrations of β-lactams for clinical isolate Klebsiella pneumoniae KP19, Escherichia coli EC56, electroporant E. coli
DH5α (pPK19), E. coli DH5α (pEC56), and reference strain E. coli DH5α.
Antimicrobial agent MIC (mg/L)
KP19 EC56 E. coli DH5α (pKP19)# E. coli DH5α (pEC56)† E. coli DH5α
Ampicillin ≥32 ≥32 ≥32 ≥32 ≤2
Cefoxitin ≥64 ≥64 ≤4 32 ≤4
Cefotaxime 128 128 0.06 0.12 0.03
Ceftazidime 32 128 0.25 1 0.25
Ceftazidime-clavulanate∗ 32 ≥128 0.25 2 0.25
Cefpirome 16 ≥64 ≤1 ≤1 ≤1
Ciprofloxacin ≥4 ≥4 ≤0.25 ≤0.25 ≤0.25
Ertapenem 2 4 ≤0.5 ≤0.5 ≤0.5
Imipenem 2 1 ≤1 ≤1 ≤1
∗Clavulanate was tested at a fixed concentration of 4 mg/L.
#E. coli DH5α (pKP19) expressed the plasmid-mediated TEM-1from K. pneumoniae 19.
†E. coli DH5α (pEC56) expressed the plasmid-mediated TEM-1 and DHA-23 from E. coli 56.
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carbapenems are regarded as the preferred agent for treat-
ment. However, the production of AmpC β-lactamase signif-
icantly increased the MICs of carbapenems was reported by
Bradford et al. with the ACT-1 β-lactamase (Bradford et al.,
1997), and by Lee et al. (2010) with the DHA-1 β-lactamase.
Based on the recombinant experiments, Martinez-Martinez et al.
(1999) demonstrated that MICs of carbapenems increased sig-
niﬁcantly in the recombinant K. pneumoniae strain harbor-
ing over expressing AmpC β-lactamase and loss of porins.
They proposed that the spread of strains that express the
plasmid-mediated AmpC β-lactamases and lack porins may cre-
ate serious therapeutic problems in the future. Furthermore,
proteomic investigation of the inner-membrane fraction of
carbapenem-resistant strain of Acinetobacter baumannii sup-
ported a model for the importance of upregulated AmpC
β-lactamases and down-regulated OmpW production in the
mediation of carbapenem resistance in A. baumannii (Tiwari
et al., 2012).
Enterobacteriaceae isolates producing a DHA-1-like enzyme
have been identiﬁed previously in Taiwan (Yan et al., 2002;
Yu et al., 2004; Wu et al., 2005). We report that DHA-type
β-lactamases remain a threat in this country. Further nationwide
surveillance should be conducted, antibiotic stewardship should
be advocated, and strict infection control measures should be
enforced.
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